Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
SURPASS-CVOT investigators
Research output: Contribution to journal › Article › peer-review
227Scopus
citations
Fingerprint
Dive into the research topics of 'Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics'. Together they form a unique fingerprint.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science